Aizikovich Alexander
AL&AM Pharmachem Ltd., Rehovot, Israel.
J Pancreat Cancer. 2020 Jun 9;6(1):40-44. doi: 10.1089/pancan.2020.0003. eCollection 2020.
New tetrahydrocannabinolic acid (THCA) derivatives ALAM027 and ALAM108 were proposed for the treatment of the pancreatic cancer disease. The effect of new cannabinoids ALAM027 and ALAM108 was tested against PANC-1 and AsPC-1 cell lines by CellTiter Glo assay. Pancreatic cancer xenograft model was used for the anticancer activity study of these compounds on PANC-1 cells. The study of new cannabinoids showed greater activity of ALAM108 than ALAM027 both for PANC-1 and AsPC-1 cells. The study of new cannabinoids on PANC-1 cells showed that their oral administration was effective in reducing tumor volume and tumor weight, and did not lead to any discomfort and weight loss of mice. The cannabinoids ALAM108 and ALAM027 inhibited the tumor growing 1.6-2 times in mice with human PANC-1 cells.
新型四氢大麻酚酸(THCA)衍生物ALAM027和ALAM108被提议用于治疗胰腺癌。通过CellTiter Glo检测法测试了新型大麻素ALAM027和ALAM108对PANC-1和AsPC-1细胞系的作用。胰腺癌异种移植模型用于研究这些化合物对PANC-1细胞的抗癌活性。对新型大麻素的研究表明,对于PANC-1和AsPC-1细胞,ALAM108的活性均高于ALAM027。对PANC-1细胞的新型大麻素研究表明,口服给药可有效减小肿瘤体积和肿瘤重量,且不会导致小鼠出现任何不适和体重减轻。大麻素ALAM108和ALAM027在携带人PANC-1细胞的小鼠中抑制肿瘤生长1.6至2倍。